UNASSIGNED: 7547 Background: Chemotherapy (CT) of elderly @entity1 with advanced @entity1149 ( @entity1149 ) is still a matter of debate. METHODS: PubMed query, using keywords simultaneously: @entity1149 , aged, antineoplastic combined CT, randomized controlled trial. Articles were also obtained by cross-checking references; abstracts from ASCO and ESMO, WCLC proceedings. The efficacy outcomes were dichotomous: Overall Response Rate (ORR) and 1-year @entity1349 ( @entity1349 ). We assessed all grade and grade    @entity137 . Hazard ratios (HRs) were calculated from the recorded events. We used EasyMA software and fixed-effect model, due to absence of statistical heterogeneity between studies. HRs < 1 meant increased survival among doublets compared with single-agents. RESULTS: Twelve eligible studies included 2,530 @entity1 (mean age 74; 1,911 @entity1 and 545 @entity1 ; 591 stage IIIB and 1,600 stage IV; 796 @entity957 , 860 @entity420 ). One-year @entity1349 significantly improved with doublets, compared with single-agents (HR 0.92; 95% CI: 0.87-0.99). HR for ORR was 1.40 (95 % CI: 1.21-1.63; p= 0.004). Doublets including @entity902 significantly improved @entity1349 (HR 0.82; 95 % CI 0.73-0.93), but not those without @entity902 . HRs for @entity390 / @entity391 , @entity1398 , @entity882 and @entity417 were significantly higher for doublets than for single-agents (1.28, CI 1.14-1.45; 1.30, CI 1.18-1.42; 1.66, CI 1.32-2.09; 1.32, CI 1.18-1.48 respectively; p=0.001). Concerning grade 3/4 @entity137 , only HRs for the biological side-effects were significantly higher for doublets: @entity1398 (1.79; 1.51-2.13), @entity882 (2.54; 1.69-3.81) and @entity417 (1.68; 1.15-2.45). CONCLUSIONS: Compared with single-agents, doublet CT significantly improved ORR and @entity1349 , specifically when including @entity902 , but haematological side-effects were more frequent. The benefit-to-risk ratio of @entity902 based doublets in advanced @entity1149 appears favourable in the elderly.

Meta-analysis of efficacy and safety of single-agent and doublet chemotherapy with or without @entity902 in advanced XXXX in the elderly.

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anaemia'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity957 :: ('MESH:D002294', 'Disease') :: ['squamous cell carcinomas'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non small cell lung cancer'] @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinomas'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity1149 :: (MESH:D002289,Disease) :: ['non-small cell lung cancer']
